KDM1A

Lysine-specific histone demethylase 1A · O60341 · KDM1A on Sugi Atlas →

322,750 patent compounds predicted against KDM1A, 155,856 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL112506	0.38	15/20
(+)-Tranylcypromine (SCHEMBL34339)	1.00	14/20
(+)-Tranylcypromine (SCHEMBL40651)	1.00	14/20
(+)-Tranylcypromine (SCHEMBL56350)	1.00	14/20
(+)-Tranylcypromine (SCHEMBL56351)	1.00	14/20
(+)-Tranylcypromine (SCHEMBL56352)	1.00	14/20
(+)-Tranylcypromine (SCHEMBL40650)	0.75	13/20
SCHEMBL93697	0.54	12/20
SCHEMBL48846	0.53	12/20
Methdilazine (SCHEMBL121507)	0.54	11/20
SCHEMBL82372	0.65	10/20
SCHEMBL10950	0.54	10/20
SCHEMBL51322	0.48	10/20
Cypenamine (SCHEMBL119769)	0.61	9/20
SCHEMBL49291	0.55	9/20
SCHEMBL48681	0.54	9/20
SCHEMBL48847	0.53	9/20
SCHEMBL102454	0.51	8/20
SCHEMBL102455	0.51	8/20
SCHEMBL91880	0.49	8/20

Clinical trials — most relevant to KDM1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2	PHASE2	ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors	PHASE2	RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans	nan	ACTIVE_NOT_RECRUITING
The Danish TURNER Cryopreservation Study	nan	RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19	nan	COMPLETED
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer	nan	UNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia	nan	UNKNOWN
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy	nan	UNKNOWN
Mechanisms of Immune Deficiency	nan	UNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a KDM1A binder may also engage these)

Protein	Name	Similarity
Q6ZQ88	—	1.000	Q6ZQ88 →
A0A8I6G2K8	—	0.998	A0A8I6G2K8 →
P25799	—	0.997	P25799 →
BRPF3	Bromodomain and PHD finger-containing protein 3	0.995	landscape →
Q99P99	—	0.995	Q99P99 →
KDM5D	Lysine-specific demethylase 5D	0.995	landscape →
Q12756	—	0.995	Q12756 →
P41230	—	0.994	P41230 →
P83038	—	0.994	P83038 →
Q5XUN4	—	0.994	Q5XUN4 →
G5EEM9	—	0.994	G5EEM9 →
Q9EQW7	—	0.993	Q9EQW7 →
A0JN40	—	0.993	A0JN40 →
Q6IQX0	—	0.993	Q6IQX0 →
O43896	—	0.993	O43896 →
Q5R607	—	0.993	Q5R607 →
F4IF36	—	0.992	F4IF36 →
Q9D1P2	—	0.992	Q9D1P2 →
Q8BMD7	—	0.992	Q8BMD7 →
Q9U3V9	—	0.992	Q9U3V9 →
Q80Y84	—	0.992	Q80Y84 →
IL4I1	L-amino-acid oxidase	0.992	landscape →
O55165	—	0.992	O55165 →
Q86BA1	—	0.992	Q86BA1 →
Q05AS3	—	0.992	Q05AS3 →
Q8LPU5	—	0.992	Q8LPU5 →
Q13415	—	0.992	Q13415 →
DHX30	ATP-dependent RNA helicase DHX30	0.992	landscape →
Q60575	—	0.992	Q60575 →
F1MAB7	—	0.991	F1MAB7 →